Browsing by Subject "Targeted therapy"
Now showing items 1-5 of 5
-
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
(Brac University, 2023-12)Researchers must prioritize non-small cell lung cancer clinical research due of its high mortality. Ongoing endeavors are being made to improve the accessibility, evaluation simplicity, and prediction accuracy of endpoints ... -
A review on targeted therapies for lung cancer
(Brac University, 2022-10)Lung cancer is one of the leading causes of cancer related deaths. The malignancy is marked by a bleak prognosis and poor clinical result, owing primarily to advanced stage at diagnosis, imposing a significant cost on ... -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
(Brac University, 2022-03)SHP2 (Src homology-2 domain-containing protein tyrosinephosphatase-2) works as a tyrosine phosphatase, to eliminate tyrosine phosphorylation in the non-receptor protein to link many oncogenic signaling pathways including ... -
Targeted therapeutic options in the treatment of Breast Cancer
(Brac University, 2022-02)The recent application of targeted therapies such as biologics, biosimilars, and other targeted biological agents in the treatment of diverse subtypes of breast cancer has been facilitated by the decoding of the human ... -
Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars
(Brac University, 2021-04)Angiogenesis is one of the pivotal factors contributing to the development and metastasis of non small cell lung cancer which is one of the most commonly diagnosed types of lung cancer. Bevacizumab, a monoclonal antibody ...
